Employees: 613
Size BioDlink International (1875.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $334M, the 857th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.36 on 18 Nov 2026.
Performance Over six months the shares fell 23.8%, against -14.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 51.1% over the last twelve months (peer median +3.0%); the operating margin is -31.2% (peer median 3.0%).
Valuation It trades at 288.2× forward earnings against a peer median of 20.7× (most expensive of 6).
Capital Return on invested capital runs 23.6 points below its cost of capital (5.5% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$563M | HK$811M | HK$1.19B | HK$863M | HK$514M |
| Revenue growth | — | -32% | +38% | +68% | — |
| Gross profit | HK$95.1M | HK$403M | HK$831M | HK$608M | HK$402M |
| EBITDA | -HK$86.3M | -HK$25.4M | HK$88.0M | -HK$994,500 | -HK$11.7M |
| Net income | -HK$181M | -HK$109M | HK$37.7M | -HK$41.7M | -HK$58.0M |
| Free cash flow | n/a | -HK$51.9M | -HK$22.3M | -HK$170M | -HK$216M |
| Capital expenditure | HK$10.1M | HK$46.7M | HK$134M | HK$225M | HK$279M |
| Total debt | n/a | HK$427M | HK$421M | HK$381M | HK$325M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1875.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | -6.4% | 7th highest of 21 |
| 6-month return | -23.8% | -14.2% | 7th lowest of 21 |
| Distance from 52-week high | -42.8% | -32.2% | 6th lowest of 21 |
| Revenue growth (TTM) | -51.1% | +3.0% | lowest of 20 |
| Operating margin | -31.2% | 3.0% | 4th lowest of 19 |
| Forward P/E | 288.2× | 20.7× | most expensive of 6 |
| ROIC minus cost of capital | -23.6 pp | -7.1 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 288.2× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 20.7× | 38.3% | -3.2% |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | n/a | 19.0% | -0.9% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | n/a | 9.2% | +6.5% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | n/a | -11.5% | +10.3% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | n/a | 14.3% | -14.0% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | n/a | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | n/a | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 24.9× | 6.1% | +62.1% |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | n/a | 8.0% | -11.3% |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 12.2× | -16.8% | +5.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | n/a | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | 12.9× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | n/a | 27.5% | -6.4% |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | n/a | 44.3% | +26.7% |